Literature DB >> 4818768

Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion.

R M MacLeod, J E Lehmeyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4818768     DOI： 10.1210/endo-94-4-1077

Source DB:  PubMed          Journal:  Endocrinology        ISSN： 0013-7227            Impact factor:   4.736


× No keyword cloud information.
  54 in total

1.  Disorders of prolactin secretion.

Authors:  M O Thorner
Journal:  J Clin Pathol Suppl (Assoc Clin Pathol)       Date:  1976

2.  The ontogenesis of human fetal hormones. III. Prolactin.

Authors:  M J Aubert; M M Grumbach; S L Kaplan
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

Review 3.  Classical dopamine agonists.

Authors:  R Horowski; P-A Löschmann
Journal:  J Neural Transm (Vienna)       Date:  2019-02-25       Impact factor: 3.575

Review 4.  Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin.

Authors:  M F Scanlon; M Pourmand; A M McGregor; M D Rodriguez-Arnao; K Hall; A Gomez-Pan; R Hall
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

5.  Effects of dopamine D-1 and D-2 receptors on intraocular pressure in conscious rabbits.

Authors:  C Prünte; I Nuttli; R Markstein; C Kohler
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

6.  The effect of ergobromocriptine on serum testosterone and prolactin levels in patients with carcinoma of the prostate.

Authors:  C Taşar; A Akdaş; Z Kirkali
Journal:  Int Urol Nephrol       Date:  1986       Impact factor: 2.370

7.  Chlorpromazine, haloperidol, metoclopramide and domperidone release prolactin through dopamine antagonism at low concentrations but paradoxically inhibit prolactin release at high concentrations.

Authors:  G M Besser; G Delitala; A Grossman; W A Stubbs; T Yeo
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

8.  Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.

Authors:  S A Fine; L A Frohman
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

9.  The PHI (PHI-27)/corticotropin-releasing factor/enkephalin immunoreactive hypothalamic neuron: possible morphological basis for integrated control of prolactin, corticotropin, and growth hormone secretion.

Authors:  T Hökfelt; J Fahrenkrug; K Tatemoto; V Mutt; S Werner; A L Hulting; L Terenius; K J Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

Review 10.  Volume transmission and its different forms in the central nervous system.

Authors:  Kjell Fuxe; Dasiel O Borroto-Escuela; Wilber Romero-Fernandez; Wei-Bo Zhang; Luigi F Agnati
Journal:  Chin J Integr Med       Date:  2013-05-15       Impact factor: 1.978
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.